These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 11809695

  • 1. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression.
    Zhang B, Prendergast GC, Fenton RG.
    Cancer Res; 2002 Jan 15; 62(2):450-8. PubMed ID: 11809695
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of Fas (CD95) expression and Fas-mediated apoptosis by oncogenic Ras.
    Fenton RG, Hixon JA, Wright PW, Brooks AD, Sayers TJ.
    Cancer Res; 1998 Aug 01; 58(15):3391-400. PubMed ID: 9699671
    [Abstract] [Full Text] [Related]

  • 3. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB, Du W, Donover S, Baker J, Liu AX, Sharp DM, Muller AJ, Prendergast GC.
    Oncogene; 2003 Jun 05; 22(23):3578-88. PubMed ID: 12789266
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE.
    Cancer Res; 2001 Dec 15; 61(24):8758-68. PubMed ID: 11751396
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1997 Sep 15; 15(11):1283-8. PubMed ID: 9315095
    [Abstract] [Full Text] [Related]

  • 6. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA, Dey S, Chendil D, Inayat MS, Mohiuddin M, Hartman G, Chatfield LK, Gallicchio VS, Ahmed MM.
    Oncogene; 2002 Nov 07; 21(51):7883-90. PubMed ID: 12420225
    [Abstract] [Full Text] [Related]

  • 7. p53 promotes selection for Fas-mediated apoptotic resistance.
    Maecker HL, Koumenis C, Giaccia AJ.
    Cancer Res; 2000 Aug 15; 60(16):4638-44. PubMed ID: 10969818
    [Abstract] [Full Text] [Related]

  • 8. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1998 Mar 15; 16(11):1467-73. PubMed ID: 9525745
    [Abstract] [Full Text] [Related]

  • 9. Effects of trichostatin A, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells.
    Park H, Lee YJ, Kim TH, Lee J, Yoon S, Choi WS, Myung CS, Kim HS.
    Int J Mol Med; 2008 Nov 15; 22(5):605-11. PubMed ID: 18949380
    [Abstract] [Full Text] [Related]

  • 10. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
    Lebowitz PF, Prendergast GC.
    Oncogene; 1998 Sep 17; 17(11 Reviews):1439-45. PubMed ID: 9779989
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The farnesyltransferase inhibitor, LB42708, inhibits growth and induces apoptosis irreversibly in H-ras and K-ras-transformed rat intestinal epithelial cells.
    Kim HS, Kim JW, Gang J, Wen J, Koh SS, Koh JS, Chung HH, Song SY.
    Toxicol Appl Pharmacol; 2006 Sep 15; 215(3):317-29. PubMed ID: 16712893
    [Abstract] [Full Text] [Related]

  • 13. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors.
    Du W, Prendergast GC.
    Cancer Res; 1999 Nov 01; 59(21):5492-6. PubMed ID: 10554025
    [Abstract] [Full Text] [Related]

  • 14. Induction of N-myc in neuroblastoma by autocrine IGF-II depends on farnesylated Ras. Application of farnesyltransferase inhibitors.
    Wittrock J, Schweizer P, Girgert R.
    Anticancer Res; 2002 Nov 01; 22(6C):4205-9. PubMed ID: 12553057
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Enhancement of tumor response by farnesyltransferase inhibitor in C3H/HeJ hepatocarcinoma.
    Kim J, Seong J, Kim SH.
    Ann N Y Acad Sci; 2004 Dec 01; 1030():95-102. PubMed ID: 15659785
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
    Morgan MA, Sebil T, Aydilek E, Peest D, Ganser A, Reuter CW.
    Br J Haematol; 2005 Sep 01; 130(6):912-25. PubMed ID: 16156861
    [Abstract] [Full Text] [Related]

  • 20. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.
    Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton AD, Muschel RJ, McKenna WG.
    Cancer Res; 1996 Apr 15; 56(8):1727-30. PubMed ID: 8620483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.